Hemostemix Inc.

HEM.V TSXV Healthcare Calgary, Canada

Loading stock data...

Financials

Stock Performance

Price History

- Drag to select time range -

From:

To:

Market Data

Market Cap 16.0M

P/E Ratio -

52-Week High -

52-Week Low -

Avg Volume -

Beta -

Forward P/E -

Dividend Yield -

EV/Revenue -

Price/Book -

Business Overview

Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.

Healthcare Biotechnology TSXV

Key Financial Metrics

Revenue

-2.6M

Net Income

C$-0.03

EPS (Diluted)

-1.9M

Free Cash Flow

Profitability

Gross Margin -

Operating Margin -

Net Profit Margin -

EBITDA -2.0M

Returns & Efficiency

Return on Assets (ROA) -263.8%

Return on Equity (ROE) -

Dividend Yield -

Payout Ratio -

Financial Health

Total Assets 991,863

Total Debt 4.9M

Debt to Equity -

Current Ratio 0.36

Company Info

Industry	Biotechnology
HQ	Calgary, Canada
Fiscal Year End	1735603200
Currency	CAD
Website	hemostemix.com

Peers

Bausch + Lomb Corporation

BLCO.TO

7.9B

P/E: --

Bausch Health Companies Inc.

BHC.TO

2.5B

P/E: 12.0

Extendicare Inc.

EXE.TO

2.5B

P/E: 23.7

Sienna Senior Living Inc.

SIA.TO

2.2B

P/E: 53.2

Cronos Group Inc.

CRON.TO

1.4B

P/E: 24.1

Tilray Brands, Inc.

TLRY.TO

1.2B

P/E: --

WELL Health Technologies Corp.

WELL.TO

1.1B

P/E: --

Knight Therapeutics Inc.

GUD.TO

631.8M

P/E: --

Insider Activity

Sentiment Bullish

Shares Bought 22,280,000

Shares Sold 0

Total Transactions 12

SEDAR+ Filings

View All Filings

No SEDAR+ filings available

Filings will appear here once they are loaded from SEDAR+

Interactive Charts

Full Chart View

Company Profile

General Information

Company Name	Hemostemix Inc.
Ticker	HEM.V
Exchange	TSXV
Sector	Healthcare
Industry	Biotechnology
Headquarters	Calgary, Canada
Fiscal Year End	1735603200
Currency	CAD
Website	hemostemix.com

Financial Summary

Market Cap	16.0M
Revenue	N/A
Net Income	-2.6M
P/E Ratio	N/A
EPS (Diluted)	C$-0.03
Net Margin	N/A
ROE	N/A
Dividend Yield	N/A

Business Description